Centalun
From Infogalactic: the planetary knowledge core
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
2-methyl-1-phenylbut-3-yne-1,2-diol
|
|
| Clinical data | |
| Legal status |
|
| Identifiers | |
| CAS Number | 2033-94-5  |
| ATC code | none |
| PubChem | CID: 16252 |
| ChemSpider | 15421  |
| Chemical data | |
| Formula | C11H12O2 |
| Molecular mass | 176.212 g/mol |
|
|
|
|
| (what is this?) (verify) |
|
Centalun was developed by Boehringer Ingelheim in 1962[1] and is a psycholeptic drug with hypnotic and sedative effects, via allosteric agonism of the GABAA receptor.[2] It was previously used for sedation in medical procedures such as surgery,[3] orthopedics[4] and gynecology,[5] although it is no longer in clinical use. Despite its history of clinical use, centalun was never incorporated into the CSA and therefore remains unregulated as a drug of abuse.
References
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This sedative-related article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Chemical articles having calculated molecular weight overwritten
- Articles with changed InChI identifier
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugs not assigned an ATC code
- Hypnotics
- GABAA receptor positive allosteric modulators
- Sedative stubs
